MOLN Molecular Partners

Molecular Partners to Present at 41st Annual JP Morgan Healthcare Conference and Swiss Investor Conferences

Molecular Partners to Present at 41st Annual JP Morgan Healthcare Conference and Swiss Investor Conferences

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in the 41st annual JP Morgan Healthcare Conference in San Francisco, CA. In addition, members of Molecular Partners management will participate in several upcoming investor events in Switzerland during January 2023.

Conference Presentation Details:

JP Morgan 41st Annual Healthcare Conference

  • Wednesday, January 11, 2023, at 10:30 am ET (4:30 pm CET)

Baader Helvea Swiss Equities Conference

  • Thursday, January 12, 2023, at 10:00 am ET (4:00 pm CET)

Conference Participation Details:

The Octavian Seminar 2023

  • Friday, January 13, 2023

All webcasted presentations will be made available on the Molecular Partners .

About Molecular Partners AG 

Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of ophthalmology, oncology, and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. ; Find us on Twitter - 

For further details, please contact:

Seth Lewis, Head of Investor Relations & Strategy

Concord, Massachusetts, U.S.



Tel:

Antonio Ligi, Head of Communications

Zurich-Schlieren, Switzerland



Tel: 1



EN
30/12/2022

Underlying

MOLNMolecular Partners

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Molecular Partners

 PRESS RELEASE
Free
MOLN Molecular Partn...

Molecular Partners appoints Martin Steegmaier as Chief Scientific Offi...

Molecular Partners appoints Martin Steegmaier as Chief Scientific Officer to drive discovery of next-gen DARPin therapeutics Extensive experience from senior oncology research roles at Roche, MorphoSys, Boehringer Ingelheim and most recently CSO at SOTIO Biotech ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced t...

August 21, 2025 1 EN
 PRESS RELEASE
Free
MOLN Molecular Partn...

Molecular Partners and Orano Med present preclinical data on mesotheli...

Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025 MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) and intended for the treatment of ovarian cancer, is nominated for development under strategic partnership with Orano MedPromising tumor accumulation and attractive biodistribution shown in vivo, selective binding to membrane-bound MSLN with positive tumor to kidney ratio ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PARIS, June 22, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 ...

June 22, 2025 1 EN
 PRESS RELEASE
Free
MOLN Molecular Partn...

Molecular Partners presents positive data from ongoing Phase 1/2a tria...

Molecular Partners presents positive data from ongoing Phase 1/2a trial of MP0533 in AML at EHA 2025 Three of eight evaluable patients with R/R AML responded after cycle 1 in ongoing cohort 8, including 1 patient with ongoing response beyond 6 monthsAcceptable safety profile across all cohorts, including in cohort 8 with steeper step-up dosingData support further dose optimization to maximize therapeutic benefit of MP0533, with dosing in cohort 9 now ongoing ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 11, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR AG ...

June 11, 2025 1 EN
 PRESS RELEASE
Free
MOLN Molecular Partn...

Molecular Partners Announces Planned Operational Efficiencies and Exte...

Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway Guidance confirmed for clinical milestones for MP0533 and MP0712 in H2 2025Cash reach now anticipated to extend into 2028 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announces that it has performed a strategic review of its cur...

June 10, 2025 1 EN
 PRESS RELEASE
Free
MOLN Molecular Partn...

Molecular Partners to Present at Upcoming Investor Conferences

Molecular Partners to Present at Upcoming Investor Conferences ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 19, 2025 (GLOBE NEWSWIRE) --  AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that members of the management team will participate in two upcoming investor conferences. H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ: Fireside Chat on Tuesday May 20, 2025 beginning at 3:30pm ET TD Cowen’s 6th Annual...

May 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch